Lungpacer Medical

Lungpacer Medical is a Canadian medical device company based in Vancouver, with operations in Philadelphia, USA. The company focuses on innovative neurostimulation therapies to enhance respiratory and critical care outcomes, particularly for patients on mechanical ventilation. Their flagship product, the AeroPace® System, is a minimally invasive technology that stimulates the phrenic nerves to activate the diaphragm. This stimulation helps rebuild diaphragm strength, allowing patients to wean off mechanical ventilators and breathe independently. The AeroPace System received U.S. FDA premarket approval in December 2024, following clinical trials that showed significant improvements in patient outcomes, including reduced ventilator days and enhanced diaphragm strength. Lungpacer Medical is also developing additional products currently in clinical trials, aimed at further supporting diaphragm function and respiratory recovery in critically ill patients. Their primary customers include hospitals and healthcare providers in intensive care units, particularly for patients with conditions like COVID-19, where diaphragm weakness is a challenge.

• Employees 50
• Founded 2009
• Annual Revenue $5500000
• Total Funding $121382217